Core Insights - Nasus Pharma Ltd. is a clinical-stage pharmaceutical company focused on developing innovative intranasal products, with management participating in investor conferences in February and March 2026 [1][2]. Group 1: Company Overview - Nasus Pharma is developing intranasal powder products aimed at addressing acute medical conditions, including NS002, an intranasal powder Epinephrine product candidate designed as a needle-free alternative for anaphylaxis treatment [3]. - The company's proprietary powder-based intranasal (PBI) technology allows for rapid and reliable drug delivery, utilizing the nasal cavity's vascular network for quick absorption [3]. Group 2: Upcoming Events - Nasus Pharma management will be available for one-on-one meetings during the Oppenheimer 36th Annual Healthcare Life Sciences Conference, BIO Investment & Growth Summit, and Citizens Life Sciences Conference [2]. - Key presentations by CEO Dan Teleman are scheduled for February 25, March 2, and March 11, 2026, with specific times and locations provided for each event [4].
Nasus Pharma to Participate in Upcoming Investor Conferences
Globenewswire·2026-02-20 13:00